Korro Bio develops RNA editing medicines for rare and common diseases, with its programs still in research or preclinical stages. It last closed at $12.32 on Nov 17, down 3.07% on the day.
Only 1 firm rated KRRO in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 21.8% upside
Based on 1 analyst who set a price target on KRRO in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $12.32.
Low $15.00Avg $15.00High $15.00
Blue marker: last close $12.32
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 20Buy$15
HC Wainwright & Co.Maintained
May 19Buy$15
CitigroupInitiated
May 18Buy$21
Raymond JamesUpgrade
Mar 13Buy$23
Date
Firm
Action
Rating
Price target
Aug 20
HC Wainwright & Co.
Reiterated
Buy
$15
May 19
HC Wainwright & Co.
Maintained
Buy
$15
May 18
Citigroup
Initiated
Buy
$21
Mar 13
Raymond James
Upgrade
Buy
$23
Loading…
Technical Analysis
KRRO · as of the Nov 17 close · updated after every close
Uptrend
The stock sits between its 20 and 50 day averages. It is 1% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the 100 day average at $12.25, and the nearest resistance the Pivot at $12.54.
Short trendBullish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$17.3552 week high+40.8%
$13.8420 day average+12.3%
$13.07Swing high (Jun 12)+6.1%
$12.92Pivot R1+4.9%
$12.54Pivot+1.8%
$12.32Last close
$12.25100 day average−0.6%
$12.16200 day average−1.3%
$11.97Swing low (Jun 25)−2.8%
$11.93Pivot S1−3.2%
$11.8450 day average−3.9%
$5.2052 week low−57.8%
Indicators
RSI (14)
44.96
Middle of its range
Neutral
MACD
0.60
Below its signal line
Bearish
Stochastic
23.6
Middle of its range
Neutral
ADX (14)
22.7
Weak trend
Williams %R
-86.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-61.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−22.3%
Change over 10 sessions
Bearish
ATR (14)
$1.28
Typical daily range, 10.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 21.6%/day
Key levels
$17.3552 week high+40.8%
$13.8420 day average+12.3%
$13.07Swing high (Jun 12)+6.1%
$12.92Pivot R1+4.9%
$12.54Pivot+1.8%
$12.32Last close
$12.25100 day average−0.6%
$12.16200 day average−1.3%
$11.97Swing low (Jun 25)−2.8%
$11.93Pivot S1−3.2%
$11.8450 day average−3.9%
$5.2052 week low−57.8%
Indicators
RSI (14)
49.82
Middle of its range
Neutral
MACD
-0.05
Above its signal line
Bullish
Stochastic
57.9
Middle of its range
Neutral
ADX (14)
13.5
No clear trend
Williams %R
-55.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
26.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.8%
Change over 10 sessions
Bearish
ATR (14)
$2.67
Typical daily range, 21.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for KRRO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KRRO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow KRRO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KRRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRRO is in one of them and how their past KRRO trades turned out.
Korro Bio is a biopharmaceutical company based in Cambridge, Massachusetts, that is developing a new class of genetic medicines that edit RNA rather than DNA. Its approach uses engineered oligonucleotides that work with a natural cell process to make precise, temporary changes to proteins. The company aims to treat both rare and widely prevalent diseases, including urea cycle disorders, liver conditions and ALS, but its programs are still in research or preclinical development.